BRUGES, BELGIUM — The development of the world’s first commercially viable poultry vaccine against foodborne Campylobacter took center stage at the Discovery to Innovation in Animal Health (DIAH) Conference, which concluded at the Bruges Meeting & Convention Centre (BMCC). This, if commercialized, could be a milestone in preventing / managing food borne zoonotic diseases and help poultry processors market their chicken products more effectively.
Lat week, (DIAH) Conference brought together an elite group of 200 international animal health executives, venture capitalists, and academic researchers specifically to bridge the gap between proof-of-concept technologies and market-ready veterinary biologicals.
A key highlight of the conference’s “Innovation Spotlight” was a technical update on the international CAMPILOBAC pipeline. This specialized consortium is racing to solve a major zoonotic challenge: neutralizing Campylobacter jejuni and Campylobacter coli at the farm gate before they enter the human food supply chain.
Zoonotic Crisis: Targeting Commensals Reservoir
Unlike highly pathogenic avian influenza, Campylobacter behaves as an asymptomatic commensal organism inside the avian /chicken gut, heavily colonizing the cecum of chickens and turkeys without causing visible disease.
Because a mere 1 to 2 log₁₀ reduction of the bacterial load in broiler intestines can decrease the human foodborne disease risk by up to 90%, a successful vaccine represents the “holy grail” of food safety. Currently, Campylobacter remains the leading cause of bacterial gastroenteritis in the European Union, generating over 246,000 confirmed human cases annually and triggering severe autoimmune complications like Guillain-Barré syndrome.
During the co-development and valuation workshops at DIAH, scientific leads outlined how the CAMPILOBAC program is overcoming the three historical barriers that have stalled previous industry vaccine attempts:
1. Advanced Antigen Selection
Instead of using crude whole-cell bacterins—which have historically delivered poor and inconsistent immune responses—the project focuses on targeting highly conserved outer membrane proteins and specific ABC transporter substrate-binding proteins (such as the CjaA antigen)
2. Overcoming Maternal Antibody Interference
Chicks are heavily protected by maternal antibodies during their first two weeks of life, a window that typically blocks early-stage vaccination. CAMPILOBAC is optimizing delivery timing to target the 21-to-28-day window when maternal immunity naturally fades, matching the period when horizontal environmental transmission spikes.
3. The Glycosylation Engine
Because Campylobacter is a highly unique bacterium that glycosylates its surface proteins, standard recombinant subunit expressions in E. coli lack the necessary conformational structures to trigger strong protective immunity. The pipeline is utilizing advanced genetic engineering to introduce functional Campylobacter protein N-glycosylation machinery into live-attenuated vectors, creating an affordable and scalable oral vaccine that can be easily administered via farm drinking water systems.
Pre-Development Valuation and Commercial Hurdles
At the conference sessions hosted by Stonehaven Analytics and animal health CRO Argenta, delegates thoroughly evaluated the financial profile of the CAMPILOBAC asset as it transitions toward Technology Readiness Levels (TRL) 5–6.
The consensus among industry corporate development teams is clear: because broilers operate on razor-thin profit margins, the vaccine’s manufacturing cost must remain exceptionally low. The asset’s current focus on a live-attenuated oral design avoids expensive purification and downstream adjuvant formulation costs, making it a highly attractive target for multi-national animal health pharmaceutical companies seeking to license the technology for global distribution.
